Home LiteratureArticle Details
PMID: 17868461 Published · epublish English Journal Article Research Support, N.I.H., Extramural

Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study.

Respiratory research ·Vol. 8 ·2007-09-14 ·Pages 64

Lee JS, Rosengart MR, Kondragunta V, Zhang Y, McMurray J, Branch RA, Choi AM, Sciurba FC

Abstract

Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome characterized by varying degrees of airflow limitation and diffusion impairment. There is increasing evidence to suggest that COPD is also characterized by systemic inflammation. The primary goal of this study was to identify soluble proteins in plasma that associate with the severity of airflow limitation in a COPD cohort with stable disease. A secondary goal was to assess whether unique markers associate with diffusion impairment, based on diffusion capacity of carbon monoxide (DLCO), independent of the forced expiratory volume in 1 second (FEV1). A cross sectional study of 73 COPD subjects was performed in order to examine the association of 25 different plasma proteins with the severity of lung function impairment, as defined by the baseline measurements of the % predicted FEV1 and the % predicted DLCO. Plasma protein concentrations were assayed using multiplexed immunobead-based cytokine profiling. Associations between lung function and protein concentrations were adjusted for age, gender, pack years smoking history, current smoking, inhaled corticosteroid use, systemic corticosteroid use and statin use. Plasma concentrations of CCL2/monocyte chemoattractant protein-1 (CCL2/MCP-1), CCL4/macrophage inflammatory protein-1 beta (CCL4/MIP-1 beta), CCL11/eotaxin, and interleukin-13 (IL-13) were inversely associated with the % FEV1. Plasma concentrations of soluble Fas were associated with the % DLCO, whereas CXCL9/monokine induced by interferon-gamma (CXCL9/Mig), granulocyte- colony stimulating factor (G-CSF) and IL-13 showed inverse relationships with the % DLCO. Systemic inflammation in a COPD cohort is characterized by cytokines implicated in inflammatory cell recruitment and airway remodeling. Plasma concentrations of IL-13 and chemoattractants for monocytes, T lymphocytes, and eosinophils show associations with increasing severity of disease. Soluble Fas, G-CSF and CXCL9/Mig may be unique markers that associate with disease characterized by disproportionate abnormalities in DLCO independent of the FEV1.

MeSH Terms
Biomarkers/blood Blood Proteins/analysis Cohort Studies Cross-Sectional Studies Cytokines/blood Emphysema/blood,physiopathology Female Forced Expiratory Volume Humans Interleukin-13/blood Male Middle Aged Pulmonary Disease, Chronic Obstructive/blood,physiopathology Respiratory Function Tests Smoking/physiopathology
Chemicals
Biomarkers Blood Proteins Cytokines Interleukin-13
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Lee Janet S
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA. [email protected]
Rosengart Matthew R
Kondragunta Venkateswarlu
Zhang Yingze
McMurray Jessica
Branch Robert A
Choi Augustine M K
Sciurba Frank C
References (55)
55 references, click to expand
  1. Solid-phase and bead-based cytokine immunoassay: a comparison.
    Methods. 2006 Apr;38(4):294-303 PMID: 16481197
  2. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
    Am J Respir Crit Care Med. 2001 Apr;163(5):1256-76 PMID: 11316667
  3. Oral corticosteroids decrease eosinophil and CC chemokine expression but increase neutrophil, IL-8, and IFN-gamma-inducible protein 10 expression in asthmatic airway mucosa.
    J Allergy Clin Immunol. 2005 Feb;115(2):280-6 PMID: 15696082
  4. Role of epidermal growth factor receptor activation in regulating mucin synthesis.
    Respir Res. 2001;2(2):85-9 PMID: 11686870
  5. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
    Respir Med. 1998 Aug;92(8):993-9 PMID: 9893764
  6. Interleukin-8 in airway inflammation in patients with asthma and chronic obstructive pulmonary disease.
    Int Arch Allergy Immunol. 1996 Feb;109(2):183-91 PMID: 8563494
  7. Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema.
    Am J Physiol Lung Cell Mol Physiol. 2005 Apr;288(4):L641-7 PMID: 15579628
  8. Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity.
    J Immunol. 2005 Aug 15;175(4):2570-8 PMID: 16081831
  9. Inflammatory response and body composition in chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1414-8 PMID: 11704588
  10. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
    Lancet. 2000 Oct 28;356(9240):1480-5 PMID: 11081531
  11. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products.
    Blood. 1992 Oct 15;80(8):2012-20 PMID: 1382715
  12. Chronic obstructive pulmonary disease is associated with enhanced bronchial expression of FGF-1, FGF-2, and FGFR-1.
    J Pathol. 2005 May;206(1):28-38 PMID: 15772985
  13. Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.
    Intern Med. 2005 Nov;44(11):1137-43 PMID: 16357450
  14. State of the art. Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice.
    Proc Am Thorac Soc. 2006 Aug;3(6):494-8 PMID: 16921126
  15. Mediators of chronic obstructive pulmonary disease.
    Pharmacol Rev. 2004 Dec;56(4):515-48 PMID: 15602009
  16. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome.
    Am J Pathol. 2002 Nov;161(5):1783-96 PMID: 12414525
  17. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2004 Oct 1;170(7):760-5 PMID: 15229100
  18. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease.
    Am J Respir Cell Mol Biol. 2002 Nov;27(5):517-25 PMID: 12397010
  19. Reference spirometric values using techniques and equipment that meet ATS recommendations.
    Am Rev Respir Dis. 1981 Jun;123(6):659-64 PMID: 7271065
  20. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.
    Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 PMID: 15824174
  21. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society.
    Am Rev Respir Dis. 1991 Nov;144(5):1202-18 PMID: 1952453
  22. Standardisation of the single-breath determination of carbon monoxide uptake in the lung.
    Eur Respir J. 2005 Oct;26(4):720-35 PMID: 16204605
  23. Intracellular cytokine profile of T lymphocytes in patients with chronic obstructive pulmonary disease.
    Clin Exp Immunol. 2006 Sep;145(3):474-9 PMID: 16907916
  24. Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis.
    Allergy. 2002 Jan;57(1):17-22 PMID: 11991282
  25. Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease.
    Proc Am Thorac Soc. 2005;2(1):78-82 PMID: 16113473
  26. Interpretative strategies for lung function tests.
    Eur Respir J. 2005 Nov;26(5):948-68 PMID: 16264058
  27. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis.
    Thorax. 2004 Jul;59(7):574-80 PMID: 15223864
  28. Standardisation of spirometry.
    Eur Respir J. 2005 Aug;26(2):319-38 PMID: 16055882
  29. Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.
    Am J Respir Crit Care Med. 2001 Jul 1;164(1):109-16 PMID: 11435248
  30. Standardization of Spirometry, 1994 Update. American Thoracic Society.
    Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36 PMID: 7663792
  31. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2006 Oct 15;174(8):867-74 PMID: 16799074
  32. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease.
    Am J Respir Crit Care Med. 2002 May 15;165(10):1404-9 PMID: 12016104
  33. Myeloperoxidase as a marker of increasing systemic inflammation in smokers without severe airway symptoms.
    Respir Med. 2007 May;101(5):888-95 PMID: 17098408
  34. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema.
    PLoS Med. 2004 Oct;1(1):e8 PMID: 15526056
  35. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination.
    Am J Med. 2003 Jun 15;114(9):758-62 PMID: 12829203
  36. The nature of small-airway obstruction in chronic obstructive pulmonary disease.
    N Engl J Med. 2004 Jun 24;350(26):2645-53 PMID: 15215480
  37. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation.
    J Immunol. 2006 Dec 1;177(11):8086-94 PMID: 17114483
  38. Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke.
    Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L165-72 PMID: 11133506
  39. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
    Respir Med. 2000 Dec;94(12):1215-20 PMID: 11192958
  40. The interactions between cigarette smoking and reduced lung function on systemic inflammation.
    Chest. 2005 Feb;127(2):558-64 PMID: 15705996
  41. International union of pharmacology. XXII. Nomenclature for chemokine receptors.
    Pharmacol Rev. 2000 Mar;52(1):145-76 PMID: 10699158
  42. Role of CCR5 in the pathogenesis of IL-13-induced inflammation and remodeling.
    J Immunol. 2006 Apr 15;176(8):4968-78 PMID: 16585593
  43. The role of epidermal growth factor in mucus production.
    Curr Opin Pharmacol. 2001 Jun;1(3):254-8 PMID: 11712748
  44. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema.
    J Clin Invest. 2000 Nov;106(9):1081-93 PMID: 11067861
  45. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.
    Science. 1994 Mar 25;263(5154):1759-62 PMID: 7510905
  46. Characterization of T lymphocytes in chronic obstructive pulmonary disease.
    PLoS Med. 2004 Oct;1(1):e20 PMID: 15526047
  47. Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics.
    Eur Respir J. 1999 Jul;14(1):160-5 PMID: 10489845
  48. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum.
    Am J Respir Crit Care Med. 2002 Nov 1;166(9):1218-24 PMID: 12403691
  49. Standardized single breath normal values for carbon monoxide diffusing capacity.
    Am Rev Respir Dis. 1981 Feb;123(2):185-9 PMID: 7235357
  50. Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema.
    Thorax. 2002 May;57(5):405-11 PMID: 11978916
  51. Proinflammatory cytokines and hemostatic system in patients with chronic obstructive pulmonary disease.
    Platelets. 1997;8(4):255-9 PMID: 16793656
  52. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils.
    Am J Physiol Lung Cell Mol Physiol. 2001 Jan;280(1):L134-40 PMID: 11133503
  53. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.
    J Clin Invest. 1999 Mar;103(6):779-88 PMID: 10079098
  54. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema.
    J Clin Invest. 2000 Dec;106(11):1311-9 PMID: 11104784
  55. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD.
    Thorax. 2002 Jul;57(7):590-5 PMID: 12096201
Article Info
Journal
Respiratory research
Abbr.
Respir Res
ISSN
1465-993X
Published
2007-09-14
Epub
2007-00-14
Pages
64
Language
English
Region
England
NLM ID
101090633
PMCID
PMC2064925
Subset
IM
Grants
NCATS NIH HHS · UL1 TR000005 · United States
NHLBI NIH HHS · K08 HL070178 · United States
NCRR NIH HHS · M01 RR000056 · United States
NHLBI NIH HHS · HL70178 · United States
NHLBI NIH HHS · P50 HL084948 · United States
NCRR NIH HHS · 5M01 RR 0056 · United States
NHLBI NIH HHS · HL084948 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]